-

Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dispensing, dosing and protection technologies, today announced its participation at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026.

Stephan Tanda, President and CEO, will present at 11:15 a.m. Eastern Standard Time. Vanessa Kanu, Executive Vice President and CFO and Gael Touya, President Aptar Pharma, will also be available.

A live audio webcast and presentation materials will be available in the "Investors" section of the Company's website at www.aptar.com.

About Aptar

Aptar is a global leader in drug delivery and consumer product, dispensing, dosing and protection technologies. Aptar serves a number of attractive end markets including pharmaceutical, beauty, food, beverage, personal care and home care. Using market expertise, proprietary design, engineering and science to create innovative solutions for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit www.aptar.com.

Contacts

Aptar Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407

Aptar Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815 479 5671

AptarGroup, Inc.

NYSE:ATR

Release Summary
Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
Release Versions

Contacts

Aptar Investor Relations Contact:
Mary Skafidas
mary.skafidas@aptar.com
+1 347 351 6407

Aptar Media Contact:
Katie Reardon
katie.reardon@aptar.com
+1 815 479 5671

More News From AptarGroup, Inc.

Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and ŌURA Collaborate to Advance Migraine Insights by Connecting Migraine Buddy® with Oura Ring...

Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tachycardia (PSVT)

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhyt...

Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America’s Most Responsible Companies by Newsweek for the Seventh Consecutive Year...
Back to Newsroom